Exciting Opportunity: Data Scientist - IBD Research Team We're expanding our world-class research team Institute of Genetics and Cancer What we're building: An AI-driven dynamic clinical decision support tool that will transform how we predict and manage outcomes for IBD patients globally. Who

We're hiring a data science post doc! Work with Charlie Lees and Catalina Vallejos (catavallejos.bsky.social) (and me!) in Edinburgh. This is a great data science and clinical collaboration leveraging longitudinal IBD biomarkers and EHR data, integrating our findings into a clinical decision support tool

Great data. Thanks to Charlie Lees group 👇👇👇👇👇👇

4 chances to shape the future of IBD care in Edinburgh Our translational research team at the University of Edinburgh is building an AI‑driven clinical decision‑support platform that will change how inflammatory bowel disease is predicted and managed worldwide. We’re adding:

Yesterday was an unforgettable day! I defended my PhD thesis. I’m deeply grateful for all the love and support from my family, colleagues, and supervisors. And so lucky to have had such a fantastic and inspiring examination panel. Thank you Fernando Gomollón , Enrique Aranda and

IBD care has reached a therapeutic adolescence: we can switch inflammatory activity off rapidly in many patients, but we cannot keep it off without chronic, costly immunosuppression, nor can we prevent disease in the first place. What do we need to fix? Move from suppression

Charlie Lees Completely agree! Wrote a little bit about how we need to move from AI for molecules/microbiomes/genomes to AI for phenotyping if we’re going to break through x.com/mattzschwartz/…

What IBD patients are saying online in 2025 Toilet-mapping apps, spare clothes in the car, a running tally of days lost to exhaustion—these are the metrics patients swap online while we debate endoscopic scores in clinic. A week of social listening puts the contrast in sharp

Grateful for the #IBD clinicians who are truly listening to patients👇🏼 Thank you for your incredible work for the IBD community Charlie Lees 🙏🏼

Eight clinical trials to watch in IBD (extracted from the latest edition of Atomic IBD) 1. TL1A Inhibition — The Next Drug ClassFirst target addressing both inflammation AND fibrosis: • Tulisokibart (Merck): Phase 3 ATLAS-UC/ARES-CD ongoing • Duvakitug (Teva/Sanofi): ~48%

This photo is simply unbeatable I’ve missed this team more than words can say. 💙 Charlie Lees Nathan Constantine-Cooke Nikolas Plevris Sat hiking with the highland cows

Go analogue

Nice to see our propensity-weighted comparison of first-line vedolizumab and tofacitinib is now published. We found that the persistence & tolerability of vedolizumab were superior to tofacitinib despite comarable rates of clinical and biomarker remission academic.oup.com/ecco-jcc/advan…

When I joined Twitter in 2010, the IBD medical community was tiny— David T. Rubin, MD Peter Higgins Edward Loftus and me sharing research. Today, patients have built a multi-billion-view ecosystem across platforms, with TikTok's #IBD reaching 552 million views. The transformation goes

Interviews with Charlie Lees and I were broadcast on STV News today. We discussed our work showing whilst advanced therapy use in ulcerative colitis has been rising in NHS Lothian, colectomies have been falling.